Akcea Therapeutics Inc Revenue Growth Rates (AKCA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Akcea Therapeutics Inc   (NASDAQ: AKCA)
 

AKCA's Revenue Growth by Quarter and Year

Akcea Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKCA Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 22.38
1st Quarter March 16.07
FY 38.45





AKCA Revenue second quarter 2020 Y/Y Growth Comment
Akcea Therapeutics Inc reported decline in Revenue in the second quarter 2020 by -15.94% to $ 22.38 millions, from the same quarter in 2019.
The contraction in the second quarter 2020 Akcea Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue decline of -15.74%.

Looking into second quarter 2020 results within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Revenue growth. While Akcea Therapeutics Inc ' s Revenue fall of -15.94% ranks overall at the positon no. 1791 in the second quarter 2020.


AKCA Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 2620.39 % -43.46 % -
3rd Quarter September - 7.17 % 43.05 % -
2nd Quarter June -15.94 % 45.31 % 29.65 % -
1st Quarter March -90.19 % 857.45 % 78.23 % -
FY   - 653.11 % 17.48 % -

Financial Statements
Akcea Therapeutics Inc 's second quarter 2020 Revenue $ 22.38 millions AKCA's Income Statement
Akcea Therapeutics Inc 's second quarter 2019 Revenue $ 26.62 millions Quarterly AKCA's Income Statement


AKCA Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 1245.68 % -46.99 % 34.13 %
3rd Quarter September - -22.54 % 5.02 % -4.81 %
2nd Quarter June 39.25 % -83.75 % 7.07 % 47.19 %
1st Quarter March -94.21 % 1506.08 % -5.16 % -
FY (Year on Year)   - 653.11 % 17.48 % -


Back to AKCA Growth rate Comparisons >> Back to AKCA Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #286
Overall #1791

Revenue Y/Y Growth Statistics
High Average Low
-1.25 % -15.74 % -30.24 %
  (Mar 31 2020)
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #286
Overall #1791
Revenue Y/Y Growth Statistics
High Average Low
-1.25 % -15.74 % -30.24 %
  (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Akcea Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1245.42 % 216.83 % -94.21 %
(Dec 31 2019)  


AKCA's II. Quarter Q/Q Revenue Comment
Akcea Therapeutics Inc achieved in the II. Quarter 2020 below company average Revenue jump of 39.25% quarter on quarter, to $ 22.38 millions.

Although the II. Quarter 2020 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the -83.75% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 56 other companies have achieved higher Revenue quarter on quarter growth. While Akcea Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 404.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #57
Healthcare Sector #89
Overall #404
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #57
Healthcare Sector #89
Overall #404
Revenue Q/Q Growth Statistics
High Average Low
1245.42 % 216.83 % -94.21 %
(Dec 31 2019)  


AKCA's II. Quarter Q/Q Revenue Comment
Akcea Therapeutics Inc achieved in the II. Quarter 2020 below company average Revenue jump of 39.25% quarter on quarter, to $ 22.38 millions.

II. Quarter 2020 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -83.75% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 56 other companies have achieved higher Revenue quarter on quarter growth. While Akcea Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 404.


Akcea Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 336.56 $ 340.80 $ 488.54 $ 221.26 $ 219.88
Y / Y Revenue Growth (TTM) 53.07 % 61.08 % 653.15 % 204.33 % 228.6 %
Year on Year Revenue Growth Overall Ranking # 113 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -1.25 % -30.24 % 120.8 % 0.63 % 3.92 %
Seq. Revenue Growth (TTM) Overall Ranking # 3286 # 1525 # 1800 # 1799 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2020 period, Akcea Therapeutics Inc 's cumulative twelve months Revenue were $ 337 millions, company would post below average annual Revenue growth of 3.92% year on year, if the fiscal year would end at Jun 30 2020.
A slow-down in the Akcea Therapeutics Inc 's Revenue growth from the 16.07% growth in Mar 31 2020.

Within the Healthcare sector 33 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 113.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 34
Overall # 113

Revenue TTM Y/Y Growth Statistics
High Average Low
653.15 %
 207.86 %
17.49 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 163
Sector # 422
S&P 500 # 3286
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2020 period, Akcea Therapeutics Inc 's cumulative twelve months Revenue were $ 337 millions, company would post below average annual Revenue growth of 17.49% year on year, if the fiscal year would end at Jun 30 2020.
A slow-down in the Akcea Therapeutics Inc 's Revenue growth from the 16.07% growth in Mar 31 2020.

Within the Healthcare sector 33 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 113.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 34
Overall # 113

Revenue TTM Y/Y Growth Statistics
High Average Low
653.15 %
207.86 %
17.49 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 163
Sector # 422
S&P 500 # 3286




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AKCA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2020
Integrated Biopharma Inc-0.36%$ -0.361 millions
Conformis inc -0.64%$ -0.638 millions
Nrc Health-0.79%$ -0.789 millions
Chimerix Inc -0.99%$ -0.989 millions
Prestige Consumer Healthcare Inc -1.19%$ -1.189 millions
Amedisys Inc-1.61%$ -1.608 millions
Sanara Medtech Inc -1.67%$ -1.667 millions
Endo International Plc-1.73%$ -1.735 millions
Sunlink Health Systems Inc -1.93%$ -1.927 millions
Novo Nordisk A-1.96%$ -1.960 millions
Healthcare Services Group Inc -2.18%$ -2.180 millions
Eli Lilly And Company-2.44%$ -2.436 millions
Myomo Inc -2.47%$ -2.472 millions
Icu Medical Inc-2.85%$ -2.851 millions
Reliv International Inc-2.91%$ -2.912 millions
Quanterix Corporation-3.00%$ -2.999 millions
United Therapeutics Corporation-3.10%$ -3.105 millions
Immunogen inc -3.33%$ -3.326 millions
Hologic Inc-3.46%$ -3.461 millions
Avantor Inc -3.50%$ -3.504 millions
Nature s Sunshine Products inc -3.79%$ -3.790 millions
American Renal Associates Holdings Inc -3.80%$ -3.800 millions
Healthlynked Corp-3.88%$ -3.880 millions
Labcorp Holdings Inc -3.92%$ -3.918 millions
Steris Plc-4.00%$ -4.000 millions
Mylan N v -4.22%$ -4.219 millions
Medpace Holdings Inc -4.25%$ -4.254 millions
Baxter International Inc -4.30%$ -4.296 millions
Pra Health Sciences Inc -4.38%$ -4.378 millions
Universal Health Services Inc -4.39%$ -4.393 millions


About Akcea Therapeutics Inc Revenue Growth Rates (AKCA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.